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Colistin has found increasing use in treating drug-resistant bacterial lung infections, but potential interactions with pulmonary
biomolecules have not been investigated. We postulated that colistin, like aminoglycoside antibiotics, may bind to secretory mu-
cin in sputum or epithelial mucin that lines airways, reducing free drug levels. To test this hypothesis, we measured binding of
colistin and other antibiotics to porcine mucin, a family of densely glycosylated proteins used as a surrogate for human sputum
and airway mucin. Antibiotics were incubated in dialysis tubing with or without mucin, and concentrations of unbound antibi-
otics able to penetrate the dialysis tubing were measured over time using liquid chromatography-tandemmass spectrometry
(LC-MS/MS). The percentage of antibiotic measured in the dialysate after 4 h in the presence of mucin, relative to the amount
without mucin, was 15% for colistin, 16% for polymyxin B, 19% for tobramycin, 52% for ciprofloxacin, and 78% for daptomy-
cin. Antibiotics with the strongest mucin binding had an overall polybasic positive charge, whereas those with comparatively
little binding were less basic. When comparingMICs measured with or without addedmucin, colistin and polymyxin B showed
>100-fold increases inMICs for multiple Gram-negative bacteria. Preclinical evaluation of mucin binding should become a
standard procedure when considering the potential pulmonary use of new or existing antibiotics, particularly those with a poly-
basic overall charge. In the airways, mucin binding may reduce the antibacterial efficacy of inhaled or intravenously adminis-
tered colistin, and the presence of sub-MIC effective antibiotic concentrations could result in the development of antibiotic
resistance.
Colistimethate (also known as colistin methanesulfate) (Fig. 1,structure 1), often referred to by the name of the active hydro-
lysis product, colistin (Fig. 1, structure 2) (1-4), is widely used as
an aerosol therapy in patients with cystic fibrosis (CF) and chronic
airway infection with Pseudomonas aeruginosa (5–8). Use of neb-
ulized colistimethate has also been reported in patients with bron-
chiectasis or with ventilator-associated pneumonia due to Gram-
negative bacteria (9, 10). The initial use of colistin in patients with
CF was reported in 1987 in a small study from Denmark (5). The
subsequent widespread adoption of colistin treatment and more
than 25 years of therapy without major adverse effects reported,
with the exception of bronchospasm, have likely contributed to
the improvement of care in patients with CF and chronic endo-
bronchial pseudomonal infection (6).
Colistimethate is an inactive prodrug of the antibiotic colistin
in which the five basic amine groups are nominally masked by
methanesulfonylation, although multiple partially derivatized
species are likely present (11). It can be administered intrave-
nously, intramuscularly, or by nebulization (note that the nebu-
lized form has regulatory approval in many European countries
but not in the United States, though a phase I clinical trial spon-
sored by the U.S. National Institute of Allergy and Infectious Dis-
eases [12] is currently recruiting 39 participants to compare
aerosolized and intravenous colistimethate sodium). While neb-
ulization of an intravenous formulation of colistimethate is gen-
erally employed for inhalation therapy, dry powder formulations
of colistimethate have also been administered (13, 14). After ad-
ministration, the prodrug is activated by slow nonspecific hydro-
lysis, releasing formaldehyde-bisulfite adducts while progressing
through a variety of partially methanesulfonylated intermediates
to eventually generate the active form of the drug, colistin sulfate
(1, 2, 8, 15). The active drug is a collection of closely related cyclic
cationic peptides, also known as polymyxin E, with the 2 major
components, known as polymyxin E1 and E2, differing only in the
fatty acidmoiety (Fig. 1) (1, 2, 4, 15). The cationic peptides disrupt
the cell membranes of Gram-negative bacteria via an initial spe-
cific interaction with the membrane component lipid A (1, 15).
These peptides are also cytotoxic tomammalian cells (16) and can
cause airway and alveolar damage at high concentrations (17).
Closely related polymyxin B (Fig. 1, structure 3) is used directly as
the active compound (polymyxin B sulfate) for intravenous, in-
tramuscular, intrathecal, or topical dosing; it is also a mixture of
peptides, with the major peptides known as polymyxin B1 and B2
(1, 2). In contrast to polymyxin B sulfate, colistin sulfate is nor-
mally not administered to humans without being masked as the
polymethanesulfonylated prodrug.
Examination of preclinical toxicology studies raises questions
about why colistimethate is so safe for pulmonary clinical use.
Development of one of the major active components of colistin
(polymyxin E1) as a potential drug for inhalation therapy was
previously abandoned, because a tolerated dose was not found in
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rat preclinical studies that evaluated inhaled doses ranging from 3
to 32 mg/kg body weight/day; significant local respiratory tract
irritationwas found at the lowest tested dosewithout any evidence
of systemic toxicity (17). A 2002 study of inhalation of a dry pow-
der formulation of colistin sulfate in six healthy patients and five
with CF, comparing dosing of 25 mg of powdered colistin sulfate
(approximately 0.4 mg/kg, lower than the lowest dose in the rat
study) to 160 mg of colistimethate in nebulized solution, found
reductions in pulmonary function in most patients and mild to
severe cough in all patients dosed with the powder but no adverse
effects in the nebulized group (18). A 2004 study compared neb-
ulized colistin sulfate (100-mg dose, approximately 1.6 mg/kg)
with nebulized colistimethate (160-mg dose, with equivalent
colistin content to the colistin sulfate dose) in nine CF patients
chronically infected with P. aeruginosa; seven of the patients could
not complete the colistin sulfate dose due to throat irritation and
severe cough and showed significant reductions in lung function
compared to thosewho received the colistimethate dose (19). Fur-
thermore, in an unfortunate accident in a patient with CF, colis-
timethate (75-mg dose) was reconstituted and allowed to convert
FIG 1 Antibiotic structures.
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to active colistin before administration, which led to fatal acute
respiratory distress syndrome (20). This established that high
doses of inhaled colistin can be toxic to humans. The actual dose
of active colistin delivered by nebulization of colistimethate solu-
tion is unknown; however, assuming (i) a conservative 15% of the
nominal dose in the nebulizer (nebulized dose is generally 1 to 2
million IU of colistin, equivalent to 80 to 160mg of colistimethate
or 33 to 67 mg of colistin [colistin base activity, the active moiety]
[21]) is delivered to the lung (a deposition efficiency of approxi-
mately 10% has been found for aerosolized tobramycin [22, 23])
and (ii) subsequent 50% conversion to active colistin (for intra-
venous dosing, only 20% to 25% is converted, due largely to sig-
nificant renal clearance of colistimethate before conversion [1];
the amount converted in the lung before being absorbed or
cleared has not been reported), then this generates an estimate of
approximately 8% of the nominal dose in the nebulizer, or 5 to 10
mg of colistin, as the exposure. However, even this exposure
would not be predicted to be safely tolerated based on clinical
studies of direct inhalation of colistin sulfate. The discrepancy in
the results may result from treatment with the entire dose of colis-
tin at once, instead of administering the precursor that slowly
converts to colistin over time (24). In addition, colistin, like ami-
noglycosides (25-28), may be bound to mucin found in sputum,
and, because of the resulting reduction in unbound antibiotic, the
active and clinically effective dose of colistin in humansmay be far
smaller than the previously reported concentrations in sputum
(21, 29). Slow release of colistin from colistimethatemay allow for
increased mucin binding compared to a rapid high dose, further
reducing the exposure to free colistin. Pharmacokinetic studies of
inhaled colistimethate in humans show that high concentrations
of colistin aremaintained in the sputum (over 10mg/liter of poly-
myxin E1 at 8 h after a single dose of 66mg), while serum concen-
trations peak at 1.5 h at 0.15 mg/liter and are below 0.05 mg/liter
by 6 h (21).
The mucin glycoproteins form the major macromolecular
constituent ofmucus, though sputum also contains other compo-
nents, such as DNA, proteins, lipids, and cellular debris (30, 31).
To test the hypothesis that colistin is bound to mucin, we mea-
sured the binding of colistin and other antibiotics to porcine
stomachmucin, a family of densely glycosylated proteins used as a
surrogate for the mucin component of human sputum. Porcine
mucin has previously been employed as a surrogate in studies
measuring the binding of tobramycin (25), where it showed sim-
ilar levels of antibiotic inhibition as sputum from a CF patient
(40% to 50% versus 60% recovery after 250 min), and has been
utilized as a component of artificial sputum (32).
The effect of sputum on antibiotic availability has previously
been studied by a number of methods, including dialysis (26),
ultrafiltration (28), and addition of sputum to bactericidal mea-
surements (27, 33).
MATERIALS AND METHODS
Study design. Studies were conducted on colistin sulfate, polymyxin B
sulfate, tobramycin, ciprofloxacin, and daptomycin (Fig. 1, structures 2
through 6) to measure binding to porcine stomach mucin. A solution of
400g of each antibiotic was incubated in dialysis tubing with or without
125mg of porcine stomachmucin, and the concentration of the unbound
antibiotic able to penetrate the dialysis tubingwas subsequentlymeasured
in the dialysates over time, with a total solution volume of 11 ml. Initial
testing was conducted at 4°C, with the colistin sulfate assay repeated at
37°C.
Antibiotic and mucin preparation. Colistin sulfate (Sigma-Aldrich,
catalog no. C4461), polymyxin B sulfate (Sigma-Aldrich, catalog no.
P0972), tobramycin (Sigma-Aldrich, catalog no. T4014), ciprofloxacin
(Sigma-Aldrich, catalog no. 17850), and daptomycin (Enzo Life Sciences,
catalog no. BML-A201-0100) were prepared as 4-mg/ml solutions in wa-
ter. A 12.5% (wt/vol) solution of mucin was prepared by dissolving 125
mg of porcine stomach mucin (Sigma-Aldrich, catalog no. M1778, type
III, bound sialic acid 0.5% to 1.5%, partially purified powder) in 1.0 ml of
Dulbecco’s phosphate buffered saline (PBS) (Life Technologies Australia
Pty Ltd., Invitrogen division, catalog no. 14190250).
Kinetics of efflux. Assessment of the kinetics of the efflux of each
antibiotic from a dialysis bag was performed as previously described (25),
with slight modifications. In brief, 400 g of each antibiotic (100 l of a
4-mg/ml solution) was added to 1 ml of calcium- and magnesium-free
PBS with or without 12.5% (wt/vol) porcine stomach mucin (Sigma-
Aldrich, catalog no. M1778). The resulting mixtures were placed in Spec-
tra/Por dialysis bags (6- to 8-kDa molecular mass cutoff, 32-mm flat
width, 20.4-mm diameter; 3.3-ml/cm volume; Spectrum Laboratories,
catalog no. 132655, Rancho Dominguez, CA), with the tube ends closed
using standard dialysis bag closures (Spectra/Por, catalog no. 5160190).
Dialysis was conducted in 10ml of PBS at 4°C in a 10-cmpolystyrene petri
dish (Nunc, catalog no. P7741) covered with a lid and gently agitated on
an orbital shaker at 20 rpm. A second colistin sulfate sample was tested at
37°C. Dialysate samples (200 l) were collected at 10 min and after 1, 2,
and 4 h, and the antibiotic concentration within each dialysate was deter-
mined by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis. The percentage of each antibiotic detected in the dialysate
was calculated relative to the theoretical total concentration based on 400
g of antibiotic in an 11-ml total volume.
LC-MS/MS analyses.Analyses of colistin sulfate, polymyxin B sulfate,
tobramycin, ciprofloxacin, and daptomycin were undertaken using the
4000 Qtrap LC-MS/MS system mass spectrometer (AB SCIEX, Framing-
ham, MA, USA). The LC-MS/MS parameters were as follows: mobile
phase A, 0.1% (vol/vol) formic acid in water; mobile phase B, 0.1% (vol/
vol) formic acid in acetonitrile; column, Atlantis T3 (2.1 mm by 50 mm;
5-m particle size; Waters Corp., Milford, MA, USA); column tempera-
ture, 40°C; flow rate, 0.35 ml/min with a gradient of 2% B for 1 min then
2% to 100% B for 4 min; and injection volume, 5 l with an autosampler
cooled to 12°C. Direct infusion initially provided the molecular ion, fol-
lowed by selective reaction monitoring (SRM) (monitoring multiple par-
ent fragment ions in a single MS run) in positive ionization mode, with
declustering potential (DP) and collision energy (CE) optimized to gen-
erate a good response signal. In these analyses, DP 60 V, but CE varied
depending upon the compound: colistin sulfate atm/z 385.9¡101.3 (CE,
30 V), polymyxin B sulfate atm/z 402.0¡101.3 (CE, 30 V), tobramycin at
m/z 468.2¡324.4 (CE, 28 V) and m/z 468.2¡163.3 (CE, 28 V), cipro-
floxacin at m/z 332.1¡288.1 (CE, 28 V), and daptomycin at m/z
811.1¡313.3 (CE, 40 V).
For each antibiotic, standards of 40, 20, 4, 2, 0.4, 0.2, 0.04, and 0.02
g/mlwere prepared in PBS solvent. Both the standards and samples were
diluted 1/10 with water before LC-MS/MS analysis.
MICmeasurement.Bacteria were obtained fromAmerican TypeCul-
ture Collection (ATCC;Manassas, VA,USA) and included Escherichia coli
(ATCC 25922), Klebsiella pneumoniae (ATCC 13883), Acinetobacter bau-
mannii (ATCC 19606), P. aeruginosa (ATCC 27853), and Staphylococcus
aureus (ATCC 25923). Bacteria were cultured in Mueller-Hinton broth
(MHB; Bacto Laboratories, catalog no. 211443) at 37°C overnight. A sam-
ple of each culture was then diluted 50-fold in fresh MHB and incubated
at 37°C for 2 to 3 h.Antibiotic stock solutionswere prepared at 1.28mg/ml
inwater, then serially diluted 2-fold across thewells of 96-well nonbinding
surface plates (NBS; Corning, catalog no. 3641). After the 2- to 3-h incu-
bation, the mid-log-phase bacterial cultures were diluted to a final con-
centration of 5 105 CFU/ml, and 50 l was added to each well, giving a
final antibiotic concentration range of 64g/ml to 0.03g/ml.MICswere
determined visually after 24 h of incubation at 37°C, with theMICdefined
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as the lowest antibiotic concentration at which no bacterial growth was
visible. To measure MICs in the presence of mucin, 0.4% and 4% mucin
(Sigma-Aldrich, catalog no.M1778) was added to themid-log-phase bac-
terial cultures and mixed gently before adding the mixture to the 96-well
plates to achieve final concentrations of 0.2% and 2%mucin. After 24 h of
incubation at 37°C, the plates with mucin were particularly cloudy, mak-
ing it difficult to determine growth/lack of bacterial growth. Therefore, 30
l of resazurin, an oxidation-reduction indicator dye for cell viability
determination (34, 35), was added to each well, and wells were incubated
for a further 3 h at 37°C. Following incubation with resazurin, MICs were
determined visually, with blue coloration indicating lack of cell viability
and pink indicating live cells/bacterial growth.
RESULTS
Binding to mucin. Previous studies measuring the binding of an-
tibiotics to sputum/mucin using the dialysis method have indi-
rectly assessed the amount of effluxed antibiotic by radioenzy-
matic assay (26), byMIC determination of the solution (26), or by
immunofluorescence (25); we have used a much more versatile
direct measurement of concentration, LC-MS/MS. The amounts
of binding to mucin varied between the tested antibiotics (Fig. 2).
Colistin sulfate, polymyxin B sulfate, and tobramycin showed
strong interactions with mucin at 4°C; after 4 h of incubation in
the presence of mucin, 6% (colistin sulfate), 5% (polymyxin B
sulfate), and 11% (tobramycin) of the compounds diffused out of
the dialysis bag and were detected in the dialysate, compared with
40% (colistin sulfate), 31% (polymyxin B sulfate), and 57% (to-
bramycin) detected in the dialysate in the absence of mucin. This
was equivalent to 15%, 16%, and 19% efflux in the presence of
mucin relative to efflux in the absence of mucin. Colistin sulfate
efflux in the absence of mucin was significantly increased at 37°C,
with 9% of the compound moving into the dialysate when incu-
bated with mucin compared with 87% moving into the dialysate
FIG 2 Antibiotic concentrations present in the dialysates. Antibiotic concentrations were measured in dialysates from samples of 400 g of each antibiotic (in
1 ml PBS) that were placed into dialysis tubing with () or without () 125 mg porcine gastric mucin at 4°C, except for the top right panel, for which data were
obtained at 37°C. The percentage of the antibiotic present in each dialysate was calculated relative to the theoretical concentration based on the total volume of
the solution.Mean and standard deviation (SD) values are plotted for assays performedmultiple times. Colistin sulfate dialysis at 4°Cwas performed in triplicate;
dialysis of ciprofloxacin and daptomycin was performed once, and the others were performed twice. Error bars for colistin sulfate at 37°C and tobramycin were
too small to show.
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whenmucin was absent. However, the relative recovery of colistin
in the presence of mucin remained relatively constant at both
temperatures (15% at 4°C, 10% at 37°C).
The interactions with mucin at 4°C were much weaker for cip-
rofloxacin and daptomycin than for the other compounds, with
14% (ciprofloxacin) and 36% (daptomycin) detected in the dia-
lysates in the presence of mucin, compared with 27% and 46%
detected, respectively, in the absence of mucin. This was equiva-
lent to 52% and 79% efflux in the presence of mucin relative to
efflux in the absence of mucin.
Effect ofmucin onMICs.Binding tomucin,which reduces the
free concentration of antibiotic, would be expected to reduce the
measured MIC potency of the antibiotics, just as high protein
binding is known to reduce antibiotic efficacy. Indeed,MICsmea-
sured in the presence of 0.2% or 2% porcine mucin showed de-
creased antibiotic potency (Table 1), which was generally consis-
tent with the extent of mucin binding observed in the dialysis
experiments (Fig. 2). Colistin sulfate and polymyxin B sulfate,
which had the highest mucin binding in the dialysis results,
showed 100-fold increases in MICs in the presence of mucin
relative to MICs in the absence of mucin. These increases in MIC
values were observed across multiple Gram-negative bacterial or-
ganisms. The presence ofmucin caused tobramycinMIC values to
consistently increase 8- to 64-fold against both Gram-negative
and Gram-positive organisms. In contrast, ciprofloxacin was
much less affected by the presence of mucin, with MIC values
increasing 2- to 4-fold for all tested organisms except E. coli. Dap-
tomycin was also much less affected by the presence of mucin,
with a 2-fold increase inMICwhen tested with oneGram-positive
organism (S. aureus).
DISCUSSION
The efflux of colistin sulfate and a closely related antibiotic, poly-
myxin B sulfate, from a dialysis bag in the presence of mucin was
less than 20% of the efflux observed in the absence of mucin. This
strong binding to mucin may partly explain the discrepancy be-
tween the human experience of aerosolized (inhaled) colistin (as
the prodrug colistimethate) as a safe drug and the toxicity of colis-
tin (as the active component, colistin or polymyxin E1) observed
in preclinical models (17) and clinical studies (18, 19). It is con-
sistent with the high sputum concentration and low systemic lev-
els of polymyxin E measured after a single inhaled dose of colisti-
methate (21), as the strong binding would prevent systemic
absorption. Secretorymucins are found in high abundance in spu-
tum as a result of mucociliary clearance from the lung. Indeed,
mucin overproduction and hypersecretion in sputum are com-
mon features of chronic pulmonary infection (30). Sputum also
contains other macromolecular components, such as DNA (31),
which have been shown to also bind to antibiotics such as tobra-
mycin (25, 27, 28); therefore, the colistin bindingmeasured in this
study may be underestimated. Normal rats have approximately
100-fold less density of submucosal glands than humans (36, 37);
therefore, their exposure to an aerosol of polymyxin E1 in the
preclinical study (17) could have been 5- to 10-fold higher than
the predicted exposure in humans if mucin binding had occurred.
In Europe, the currently used nebulizer dose of the colistimethate
prodrug is 2 million units, or 160 mg, although it is important to
note that the labeling of colistimethate dosing varies with the
product, as does the exact composition of different brands of
colistimethate (1, 2, 11). However, the actual exposure to the ac-
tive drug polymyxin E is far less because of loss due to inefficiency
of the nebulizer, an unknown but potentially low rate of conver-
sion of prodrug to active polymyxin E, and the additional5-fold
reduction in the concentration of active polymyxin E caused by
binding to mucin.
The results showing that tobramycin binds to mucin are con-
firmatory of previous studies that showed reduced activity of to-
bramycin in the presence of sputum from patients with CF (26).
Further, the moderate binding of ciprofloxacin to mucin that was
observed (52% recovery), though less strong than the binding of
colistin (15% recovery) and tobramycin (19%recovery),may help
explain the rapid emergence of ciprofloxacin-resistant bacteria in
CF patients receiving oral ciprofloxacin therapy (38), since mucin
binding of ciprofloxacin may lead to airway concentrations that
are below the MICs required to inhibit bacterial growth (39).
One limitation of these studies is that, in the absence of mucin,
efflux did not reach 100% in the dialysates for any of the antibiot-
ics, with the highest levels of efflux (87%) achieved with colistin
sulfate at 37°C. This could be due to insufficient incubation time
or to the binding of the antibiotics to the polystyrene plates, dial-
ysis bags (regenerated cellulose), or bag closures; such nonspecific
binding might have been reduced by the addition of a surfactant
(polysorbate 80) (40). Another limitation is that mucin only rep-
resents one of the components of sputum; binding to DNA com-
ponents, as observed for tobramycin, could potentially reduce the
amount of free colistin even more. Further, antibiotic activity can
also be inhibited by other substances found in the airways; e.g.,
daptomycin is inhibited by pulmonary surfactant (41).
TABLE 1 MIC of antibiotics in MHB with and without added mucin
Isolate and antibiotic
MIC (g/ml) in:
MHB alone 0.2% mucin 2% mucin
E. coli ATCC 25922
Colistin sulfate 0.03 0.5 64
Polymyxin B sulfate 0.03 1 64
Tobramycin 0.5/1 1 16
Ciprofloxacin 0.03 0.06 0.25
K. pneumoniae ATCC 13883
Colistin sulfate 0.5 16 64
Polymyxin B sulfate 0.5 8 64
Tobramycin 0.25 0.5 8
Ciprofloxacin 0.06 0.03 0.25
A. baumannii ATCC 19606
Colistin sulfate 0.125 0.5 64
Polymyxin B sulfate 0.03 0.5 64
Tobramycin 4 4 32
Ciprofloxacin 0.5 0.5 2
P. aeruginosa ATCC 27853
Colistin sulfate 0.06 4 64
Polymyxin B sulfate 0.06 1 64
Tobramycin 0.125 0.5 8
Ciprofloxacin 0.25 0.25 1
S. aureus ATCC 25923
Tobramycin 0.125 0.5 8
Ciprofloxacin 0.5 0.5 1
Daptomycin 1 1 2
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The levels of binding to mucin generally showed good corre-
spondence with decreases inMIC valuesmeasured in the presence
of mucin. Colistin sulfate and polymyxin B sulfate, with 15% to
16% recovery in mucin binding experiments, exhibited 100-
fold increases in measured MIC values in the presence of mucin.
Tobramycin (19% recovery in the presence ofmucin) exhibited 8-
to 64-fold increases in MIC. In contrast, ciprofloxacin, with less
binding to mucin (52% recovery), generally had 2- to 4-fold in-
creases in MICs in the presence of mucin, and daptomycin (78%
recovery) had a 2-fold increase for the one organism against which
it was tested.
Examination of the drug structures tested in these analyses
(Fig. 1) shows that those with the strongest mucin binding (colis-
tin sulfate, polymyxin B sulfate, and tobramycin) have multiple
primary amine groups, with an overall polybasic positive charge.
In contrast, the smallmolecule ciprofloxacin and the large peptide
antibiotic daptomycin, with comparatively little mucin binding,
are less basic in character.
The finding that colistin binds to mucin, a key component in
sputum, means that modeling the pharmacodynamics of aerosol-
ized colistimethate has now become even more complicated. It
will be necessary to account for (i) the time from reconstitution to
administration (because active drug is being created after recon-
stitution; while analytical studies suggest that this rate is excep-
tionally low [24], the amount of conversion to active drug may
depend on how the reconstituted drug is stored [20, 24]); (ii) the
amount of aerosol deposited from the nominal dose in the nebu-
lizer; (iii) the rate of conversion to the active drug in the airway
(which is complicated by the presence of partially deprotected,
partially active intermediates [11]); (iv) the airway clearance of
both the active drug and the prodrug; and now (v) the effect of
mucin binding. Furthermore, the use of colistimethate aerosols in
diseases other than CF, such as ventilator-associated pneumonia,
may require a much lower dose to be both safe and effective, since
patients with other diseases are likely have sputum volumes and
mucin concentrations that differ from those of CF patients or to
have sputum volumes that are variable across the course of the
disease. Pharmacokinetic evaluation of colistin is also complicated
by the fact that samples can continue to convert from the prodrug
to the active form after recovery from the patient, therebymaking
elucidation of active drug levels in vivo inaccurate (42). However,
the strong binding of colistin to mucin suggests that preclinical
evaluation of such binding should become a standard procedure
when considering the potential use of any antibiotic as an aerosol,
particularly those with a polybasic overall positive charge.
With the development of multidrug resistant (MDR) Gram-
negative bacteria, colistin has been highlighted as an effective
choice of antibiotics (43, 44). However, mucin binding in the air-
ways may reduce the antibacterial efficacy of both inhaled and
intravenously administered colistin, leading to insufficient antibi-
otic levels in sputum to kill bacteria once mucin binding is taken
into account, fostering the generation of resistant populations due
to constant exposure to sublethal doses. This may help explain
why resistance arises within patients undergoing colistin therapy,
as shown in a recent study demonstrating the emergence of colis-
tin-resistant A. baumannii following treatment of carbapenem-
resistant, colistin-susceptible infections with intravenous and/or
inhaled colistimethate (45). Further examination of the kinetics of
colistin exposure, the rate of colistimethate unmasking in sputum
after inhalation delivery, and the rate of colistin and colistimethate
clearance is required in order to determine whether a slow but
sustained release of colistin from colistimethate is more effective
than a rapidly achieved high concentration of colistin produced
via inhalation of colistin and to determine whether a smaller, tol-
erable, yet effective dose of inhaled colistin sulfate can be found.
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